Yap Taz Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also known as WWTR1) are the principal transcriptional coactivators of the Hippo signaling pathway. Originally discovered as oncogenic proteins, YAP/TAZ have emerged as crucial regulators of neural stem cell proliferation, neuronal differentiation, brain development, and adult neurogenesis [1]. Recent research reveals that YAP/TAZ signaling is dysregulated in multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS, where they influence neuronal survival, neuroinflammation, and regenerative responses [2]. [1]
| Component | Type | Function in Neurodegeneration | [2]
|-----------|------|------------------------------| [3]
| YAP | Transcriptional Coactivator | Regulates gene expression, cell survival | [4]
| TAZ/WWTR1 | Transcriptional Coactivator | YAP homolog, overlapping functions | [5]
| MST1/2 | Ser/Thr Kinases | Hippo pathway kinases | [6]
| LATS1/2 | Ser/Thr Kinases | Phosphorylate YAP/TAZ | [7]
| TEAD1-4 | Transcription Factor | Primary DNA-binding partners | [8]
| CTGF | Target Gene | Connective tissue growth factor | [9]
| CYR61 | Target Gene | Cellular communication network factor |
| 14-3-3 | Adapter Protein | Binds phosphorylated YAP/TAZ |
| SAV1 | Scaffold Protein | Hippo pathway component |
YAP/TAZ signaling is significantly altered in AD [3]:
YAP/TAZ play protective roles in PD models [4]:
| Agent | Mechanism | Status |
|---|---|---|
| YAP/TAZ agonists | Promote nuclear localization | Preclinical |
| Hippo inhibitors | Block MST1/2 or LATS1/2 | Research phase |
| TEAD modulators | Enhance TEAD-YAP interaction | Preclinical |
| Approach | Rationale | Status |
|---|---|---|
| MST1 inhibitors | Reactivate YAP/TAZ | Preclinical |
| LATS1/2 inhibitors | Prevent YAP/TAZ phosphorylation | Research |
| Calcium channel modulation | Affects Hippo signaling | Research |
| Biomarker | Sample | Relevance |
|---|---|---|
| YAP nuclear/cytoplasmic ratio | Brain tissue | Pathway activity |
| p-YAP (Ser127) | Brain tissue | Inhibition marker |
| CTGF levels | CSF, brain tissue | YAP/TAZ target |
| CYR61 levels | CSF, brain tissue | YAP/TAZ target |
The study of Yap Taz Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this mechanism.
'YAP/TAZ in neurodegeneration: Emerging roles and therapeutic potential'. 2022. ↩︎
'Hippo pathway in Alzheimer''s disease: From pathogenesis to therapy'. 2021. ↩︎
TAZ regulates autophagy in neurodegenerative diseases. 2021. ↩︎
YAP/TAZ in adult neural stem cells and neurogenesis. 2020. ↩︎
'Hippo pathway in ALS: Role in motor neuron degeneration'. 2021. ↩︎
YAP-mediated neuroprotection after ischemic stroke. 2020. ↩︎
YAP/TAZ-TEAD transcriptional co-activation in brain disease. 2021. ↩︎
Cross-talk between Hippo and other pathways in neural development. 2021. ↩︎